Mint Tower Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-15,000
Closed -$2.42M 290
2022
Q4
$2.42M Sell
15,000
-22,000
-59% -$3.37M 0.22% 76
2022
Q3
$4.97M Sell
37,000
-600
-2% -$86.1K 0.39% 51
2022
Q2
$5.76M Sell
37,600
-14,600
-28% -$2.23M 0.46% 41
2022
Q1
$8.46M Buy
52,200
+38,000
+268% +$5.52M 0.79% 21
2021
Q4
$1.92M Sell
14,200
-7,100
-33% -$839K 0.25% 85
2021
Q3
$2.3M Buy
21,300
+2,500
+13% +$286K 0.29% 65
2021
Q2
$2.12M Sell
18,800
-14,700
-44% -$1.66M 0.15% 112
2021
Q1
$3.58M Buy
33,500
+16,500
+97% +$1.76M 0.34% 35
2020
Q4
$1.8M Buy
+17,000
New +$1.63M 0.24% 23
2020
Q1
Sell
-50,000
Closed -$4.43M 231
2019
Q4
$4.43M Hold
50,000
0.59% 46
2019
Q3
$3.79M Buy
+50,000
New +$3.43M 0.55% 40

Other funds holding ABBV

Mint Tower Capital Management's ABBV Position: Q4 2022 in Review

Mint Tower Capital Management sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 4,008 shares — an estimated $615K sold.

Mint Tower Capital Management first reported a position in ABBV in Q2 2021 and held it in 3 quarters. The position peaked at $538K in Q3 2022. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

  • Mint Tower Capital Management reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
  • Mint Tower Capital Management sold 4,008 AbbVie shares in Q4 2022, an estimated $615K.
  • Mint Tower Capital Management first reported a position in AbbVie in Q2 2021 and held it in 3 quarters.
  • Mint Tower Capital Management's AbbVie position peaked at $538K in Q3 2022.
  • 3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Mint Tower Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.